Literature DB >> 23945063

A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.

Srividya Iyer1, Nicola Banks, Marc-André Roy, Phil Tibbo, Richard Williams, Rahul Manchanda, Pierre Chue, Ashok Malla.   

Abstract

OBJECTIVE: Despite the well-acknowledged problem of poor adherence to antipsychotic (AP) medication, long-acting injectables (LAIs) that could improve adherence are underused in Canada. Attitudes concerning LAIs among patients and psychiatrists may contribute to this underuse. Our objective was to investigate perceptions of and attitudes toward LAIs among patients in Canada.
METHOD: Focus groups were conducted with 34 patients with a diagnosis of schizophrenia spectrum psychoses in 4 Canadian provinces. The focus groups inquired about experiences with and attitudes toward LAI APs. The sessions were audiotaped and transcribed verbatim, and transcripts were coded using a combination of deductive and inductive methods.
RESULTS: Four themes emerged: awareness of and knowledge about LAIs; perceptions about LAIs; cost and convenience considerations; and issues arising from the coercive context under which LAIs were often prescribed. Nine patients had never heard about LAIs, and some others reported not having understood what was discussed with them regarding LAIs. Patients had typically heard about LAIs in either a context of coercion or of medication nonadherence. Patients had positive and negative perceptions concerning LAIs. The positive perceptions centred on relapse prevention and reduced effort in ensuring adherence, and the negative perceptions centred on financial costs and the inconvenience of appointments to receive injections.
CONCLUSION: To enhance LAI usage, some of the issues that need to be addressed are the inadequacy of information given to patients, the element of coercion involved in LAI introduction, the pragmatic barriers to LAI uptake by patients, and negative subjective perceptions about LAIs.

Entities:  

Keywords:  antipsychotic long-acting injections; focus group; long-acting depot antipsychotics; patient attitudes

Mesh:

Substances:

Year:  2013        PMID: 23945063     DOI: 10.1177/088740341305805s03

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  12 in total

Review 1.  [Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].

Authors:  S Breit; G Hasler
Journal:  Nervenarzt       Date:  2016-07       Impact factor: 1.214

Review 2.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

3.  A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.

Authors:  Morgan M Philbin; Carrigan Parish; Sadie Bergen; Deanna Kerrigan; Elizabeth N Kinnard; Sarah E Reed; Mardge H Cohen; Oluwakemi Sosanya; Anandi N Sheth; Adaora A Adimora; Jennifer Cocohoba; Lakshmi Goparaju; Elizabeth T Golub; Margaret Fischl; Maria L Alcaide; Lisa R Metsch
Journal:  AIDS Patient Care STDS       Date:  2021-01       Impact factor: 5.078

Review 4.  Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Authors:  Georgia L Stevens; Gail Dawson; Jacqueline Zummo
Journal:  Early Interv Psychiatry       Date:  2015-09-25       Impact factor: 2.732

5.  Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.

Authors:  Sally Mustafa; Joanna Bougie; Maia Miguelez; Guerline Clerzius; Emmanouil Rampakakis; Jean Proulx; Ashok Malla
Journal:  BMC Psychiatry       Date:  2019-04-16       Impact factor: 3.630

6.  Patients' experiences of long-acting injectable antipsychotics: a qualitative study.

Authors:  Lin-Ling Chiu; Chun-Hao Liu; Shu-Chung Lii; Chun-Lin Chu; Huang-Li Lin
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-03       Impact factor: 2.570

7.  The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing.

Authors:  Lefan Jin; Yun Chen; Junli Zhu; Qingzhi Huang; Bin Li; Ying Xu; Rui Xi; Wei Lu
Journal:  Front Public Health       Date:  2021-11-19

8.  Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy.

Authors:  Giovanni Ostuzzi; Maria Angela Mazzi; Samira Terlizzi; Federico Bertolini; Andrea Aguglia; Francesco Bartoli; Paola Bortolaso; Camilla Callegari; Mariarita Caroleo; Giuseppe Carrà; Mariangela Corbo; Armando D'Agostino; Chiara Gastaldon; Claudio Lucii; Fabio Magliocco; Giovanni Martinotti; Michela Nosé; Edoardo Giuseppe Ostinelli; Davide Papola; Marco Piero Piccinelli; Alberto Piccoli; Marianna Purgato; Tommaso Tabacchi; Giulia Turrini; Mirella Ruggeri; Corrado Barbui
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

9.  Qualitative systematic review of barriers and facilitators to patient-involved antipsychotic prescribing.

Authors:  Rebecca Pedley; Caitlin McWilliams; Karina Lovell; Helen Brooks; Kelly Rushton; Richard J Drake; Barnaby Rumbold; Vicky Bell; Penny Bee
Journal:  BJPsych Open       Date:  2018-01

10.  Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting.

Authors:  Rosaria Di Lorenzo; Paola Ferri; Michela Cameli; Sergio Rovesti; Chiara Piemonte
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.